INT201131

Context Info Confidence 0.24 First Reported 2007 Last Reported 2007 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 6 Disease Relevance 0.90 Pain Relevance 0.08

plasma membrane (QRFPR) signal transducer activity (QRFPR)

Anatomy Link Frequency blood 1 QRFPR (Homo sapiens)

Pain Link Frequency Relevance Heat headache 42 81.48 pruritus 12 5.00 Bioavailability 12 5.00 abdominal pain 6 5.00

Disease Link Frequency Relevance Heat Diarrhoea 18 85.44 Vomiting 30 84.88 Respiratory Tract Infection 6 83.56 Dizziness 60 82.64 Headache 42 81.48 Malaria 108 68.84 Congenital Anomalies 6 62.16 Arrhythmias 2 Under Development 24 49.28 Heart Disease 6 35.28 Disease 12 28.84

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The greater urinary excretion of AQ-13 and CQ than their more water-soluble metabolites (Tables 4 and 5) [26] is consistent with the active transport of CQ, and possibly AQ-13, by organic cation transporters such as organic cation transporter-like 2 (ORCTL2) [46].

Localization (excretion) of AQ-13

1) Confidence 0.24 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0

In addition to the blood samples, twenty-four hour urine collections were obtained for 3 d after the 1,500/1,750 mg therapeutic dose to evaluate the urinary excretion of AQ-13, CQ, and their metabolites.

Localization (excretion) of AQ-13 in blood

2) Confidence 0.24 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0

Fisher exact test or Pearson chi-square was used to compare the frequencies of the AEs reported for AQ-13 and CQ at each dose, and between African Americans and persons of European descent.

Localization (reported) of AQ-13

3) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0

Before the 1,500 mg therapeutic dose, 13 volunteers received a 700 mg adjustment dose of AQ-13 to compensate for the more rapid clearance of AQ-13.

Localization (clearance) of AQ-13

4) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.14 Pain Relevance 0

The data collected in this trial also showed that both AQ-13 and CQ were absorbed into the bloodstream in a similar way, but AQ-13 was absorbed more slowly than CQ.

Localization (absorbed) of AQ-13

5) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Abstract Doc Link PMC1764434 Disease Relevance 0.61 Pain Relevance 0.08

Before the 1,500 mg therapeutic dose, 13 volunteers received a 700 mg adjustment dose of AQ-13 to compensate for the more rapid clearance of AQ-13.

Localization (clearance) of AQ-13

6) Confidence 0.22 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.